ARA-290 vs Epithalon
Side-by-side comparison of key properties, dosing, and research.
- Summary
- ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
- Epithalon is a synthetic tetrapeptide developed from the pineal gland extract Epithalamin by Russian scientist Dr. Vladimir Khavinson. It is one of the most researched longevity peptides, known for activating telomerase and extending telomere length — the molecular hallmarks of cellular aging.
- Half-Life
- ~2–4 hours (SC administration)
- 2–4 hours
- Admin Route
- SubQ
- SubQ, Sublingual
- Research
- —
- —
- Typical Dose
- 4 mg (fixed dose)
- 5–10 mg total per cycle
- Frequency
- Once daily
- 0.5–1 mg daily
- Key Benefits
- Reduces neuropathic pain from small fiber neuropathy
- Anti-inflammatory without immune suppression
- Tissue protection after ischemia/reperfusion injury
- Promotes nerve fiber regeneration
- Improves symptoms of sarcoidosis-associated neuropathy
- May reduce insulin resistance and improve metabolic health
- Shown to improve autonomic neuropathy symptoms
- Activates telomerase enzyme, extending telomere length
- May slow cellular and biological aging
- Regulates melatonin production and circadian rhythms
- Improves sleep quality
- Powerful antioxidant properties
- May reduce incidence of age-related diseases
- Supports immune system function
- Studied for cancer prevention properties in animal models
- Side Effects
- Injection site reactions
- Mild fatigue at initiation
- Transient warm sensation post-injection
- Rare: mild headache
- Injection site irritation (mild)
- Temporary sleep changes during cycle (usually improves)
- Rare: fatigue
- Stacks With
- —
- —